News
Valbiotis Announces the First Visit of the First Patient in the TOTUM•63 Mode of Action Clinical Study Conducted by the INAF1, in Partnership With Nestlé Health Science
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
Sensorion Announces the Publication of Its 2021 Annual Financial Report
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Sensorion Full-Year 2021 Financial Results and Business Highlights
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Pharnext: Pharnext Reports Full Year 2021 Financial Results and Recent Business Updates
SPAC: Postponement of the General Meeting of Shareholders
Median Technologies Reports Full-Year 2021 Results and Business Indicators for the First Quarter of 2022
Regulatory News:
Median Technologies (Euronext Growth - ALMDT) (Paris:ALMDT) whose Board of Directors met on April 20, 2022 to close the consolidated financial statements for the year ending
Sensorion Will Participate in Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit Held Virtually on April 26, 2022
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
ROCTOOL: Saint-Gobain and Roctool combine their unique technologies to boost the composite and thermoplastic 3D textile preform parts manufacturing
Sensorion to Attend the Kempen Life Sciences, Cell & Gene Meeting on the Mediterranean Conferences in April 2022
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
ABIONYX Pharma Reports Positive Interim Results From Phase 2a Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury
Regulatory News:
ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today
Valbiotis präsentiert positive Ergebnisse seiner klinischen Studie zur Bioverfügbarkeit und Wirkungsweise von TOTUM•070 gegen Hypercholesterinämie
Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, qualifiziert für PEA/SME), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung
ABIONYX Pharma Receives FDA Orphan Drug Designation (ODD) for CER-001 for the Treatment of LCAT Deficiency Presenting as Kidney Dysfunction and/or Ophthalmologic Disease
Regulatory News:
ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies for
Valbiotis Announces the Positive Results of Its Clinical Study on the Bioavailability and Mode of Action of TOTUM•070, Against Hypercholesterolemia
Regulatory News:
Valbiotis (FR0013254851 - ALVAL, PEA-SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
Median Technologies Brings Forward Its 2021 Annual Results Publication to April 21, 2022
Regulatory News:
Median Technologies (ALMDT:PA) (Paris:ALMDT) announces today that the company will publish its 2021 annual results on April 21, 2022 after trading. The 2021 annual results
Sensorion Will Present at The H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference on March 30th, 2022
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
ABIONYX Announces Positive Clinical Findings for CER-001 in Treating COVID-19, Published in Biomedecines, Demonstrating That CER-001 Limits Inflammation Effects
Regulatory News:
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies for
Sensorion Provides Preliminary Documents for the Extraordinary General Meeting of April 14th, 2022
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Median Technologies Announces Design Completion of its iBiopsy® Lung Cancer Screening End-to-end CADe/CADx Software as Medical Device (SaMD) with Outstanding Sensitivity & Specificity Performance
Regulatory News:
Median Technologies (ALMDT:PA) announces outstanding performance of its iBiopsy LCS AI/ML tech-based end-to-end CADe/CADx Software as Medical Device, intended to enable early
Valbiotis verstärkt sein CSR-Engagement durch den Beitritt zum United Nations Global Compact und die Anwendung der Norm ISO 26000
Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
Valbiotis is Strengthening Its Commitment to CSR by Joining the United Nations Global Compact and Applying the ISO 26000 Standard
Regulatory News:
Valbiotis (Paris:ALVAL) (FR0013254851 - ALVAL, eligible for PEA / SME), a Research and Development company committed to scientific innovation for preventing and combating
Sensorion Will Present at the Bioprocessing Summit Europe Conference on March 22, 2022 in Barcelona
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Sensorion Update on SENS-401
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Valbiotis veröffentlicht Geschäftsbericht für 2021
Pflichtmitteilung:
Valbiotis (FR0013254851 – ALVAL, PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und
Valbiotis Publishes Its 2021 Annual Report
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases
Valbiotis kündigt bevorstehende organisatorische Änderungen im Vorstand an
Valbiotis (FR0013254851 – ALVAL, PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von